The board of Xeris Biopharma Holdings, Inc. increased its size from eight to nine members and appointed Menassie Taddese as a Class II director effective November 2, 2026. Mr. Taddese joins the Audit Committee and brings nearly 30 years of experience in global biopharmaceutical leadership, including roles at Viatris and Pfizer. He receives an initial equity award valued at approximately $450,000 and is eligible for annual grants of roughly $300,000 starting in 2027. Xeris Biopharma Holdings, Inc. develops and commercializes innovative medicines for endocrine and rare diseases.
